We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+16.84%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$5.13B
AUM Growth
-$201M
Cap. Flow
-$504M
Cap. Flow %
-9.84%
Top 10 Hldgs %
88.73%
Holding
94
New
14
Increased
25
Reduced
6
Closed
34

Top Buys

Rank Stock Value
1
GS icon
Goldman Sachs
GS
+$30.9M
2
CELG
Celgene Corp
CELG
+$26.8M
3
BAC icon
Bank of America
BAC
+$13.5M
4
APTV icon
Aptiv
APTV
+$12M
5
C icon
Citigroup
C
+$10.4M

Top Sells

Rank Stock Value
1
LNKD
LinkedIn Corporation
LNKD
+$22.5M
2
YUM icon
Yum! Brands
YUM
+$21.9M
3
MBLY
Mobileye N.V.
MBLY
+$14.8M
4
GM icon
General Motors
GM
+$13.6M
5
V icon
Visa
V
+$13.6M

Sector Composition

Rank Sector Weight
1 Consumer Staples 57.56%
2 Healthcare 18.9%
3 Consumer Discretionary 9.33%
4 Financials 2.31%
5 Industrials 0.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BUFF
1
DELISTED
Blue Buffalo Pet Products, Inc
BUFF
$2.95B 57.56%
114,987,547
– –
LXRX icon
2
Lexicon Pharmaceuticals
LXRX
$1.03B
$687M 13.41%
57,517,977
– –
WW
3
DELISTED
WW International
WW
$428M 8.35%
29,443,300
– –
GS icon
4
CALL
Goldman Sachs
GS
$293B
$157M 3.06%
1,000,000
+250,000
+33% +$38.7M
BIIB icon
5
CALL
Biogen
BIIB
$31.9B
$104M 2.03%
400,000
+50,000
+14% +$13.2M
BAC icon
6
CALL
Bank of America
BAC
$434B
$60.8M 1.19%
+4,500,000
New +$60.7M
AAPL icon
7
CALL
Apple
AAPL
$5.03T
$43.6M 0.85%
+1,600,000
New +$39.9M
INCY icon
8
Incyte
INCY
$25.7B
$43.5M 0.85%
600,000
+30,000
+5% +$2.24M
ALNY icon
9
Alnylam Pharmaceuticals
ALNY
$38.4B
$37.7M 0.73%
600,000
+125,000
+26% +$8.31M
CELG
10
DELISTED
Celgene Corp
CELG
$36M 0.7%
360,000
+260,000
+260% +$26.8M
WMT icon
11
CALL
Walmart Inc
WMT
$902B
$34.2M 0.67%
1,500,000
-3,495,000
-70% -$76.6M
BMRN icon
12
BioMarin Pharmaceuticals
BMRN
$12B
$33M 0.64%
400,000
+125,000
+45% +$10.2M
MET icon
13
CALL
MetLife
MET
$62.5B
$33M 0.64%
841,500
-841,500
-50% -$31.5M
GS icon
14
Goldman Sachs
GS
$293B
$31.4M 0.61%
+200,000
New +$30.9M
CELG
15
CALL
DELISTED
Celgene Corp
CELG
$30M 0.59%
300,000
-500,000
-63% -$51.5M
BABA icon
16
Alibaba
BABA
$275B
$29.6M 0.58%
375,000
+75,000
+25% +$5.28M
NKTR icon
17
Nektar Therapeutics
NKTR
$2.35B
$27.5M 0.54%
133,333
+26,666
+25% +$5.12M
TEVA icon
18
CALL
Teva Pharmaceuticals
TEVA
$39.9B
$24.1M 0.47%
450,000
– –
KITE
19
DELISTED
Kite Pharma, Inc.
KITE
$22.3M 0.43%
485,000
+135,000
+39% +$6.54M
BLUE
20
DELISTED
bluebird bio
BLUE
$21.3M 0.41%
38,600
+10,808
+39% +$6.64M
C icon
21
CALL
Citigroup
C
$217B
$20.9M 0.41%
500,000
+250,000
+100% +$10.4M
APTV icon
22
Aptiv
APTV
$12.5B
$20.6M 0.4%
275,000
+175,000
+175% +$12M
MA icon
23
Mastercard
MA
$497B
$18.9M 0.37%
200,000
-100,000
-33% -$8.84M
JPM icon
24
CALL
JPMorgan Chase
JPM
$930B
$14.8M 0.29%
250,000
-600,000
-71% -$35M
IONS icon
25
Ionis Pharmaceuticals
IONS
$9.06B
$14.2M 0.28%
350,000
– –
1
2 3 4

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2016 Portfolio in Review

As of Q1 2016, Artal Group held 94 positions worth $5.13B, down 3.8% from $5.33B the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Artal Group withdrew a net $504M in Q1 2016, closing 34 positions and reducing 6 holdings. Its most notable exit was LinkedIn Corporation, an estimated $22.5M position sold in full.

By sector, the portfolio is most concentrated in Consumer Staples at 58% of assets, up from 40% a quarter earlier, followed by Healthcare and Consumer Discretionary.

Against the trend, Artal Group opened a new position in Goldman Sachs worth $31.4M.

  • Artal Group's largest Q1 2016 buy was Goldman Sachs: 200,000 shares worth $31.4M.
  • Artal Group added most to Celgene Corp in Q1 2016, an estimated $26.8M increase.
  • Artal Group's biggest Q1 2016 reduction was Mastercard, cutting an estimated $8.84M.
  • Artal Group fully exited LinkedIn Corporation in Q1 2016, selling an estimated $22.5M.
  • Artal Group's ten largest holdings make up 89% of its $5.13B portfolio in Q1 2016.
  • Artal Group opened 14 new positions and closed 34 in Q1 2016.
  • Artal Group's portfolio value fell 3.8% quarter-over-quarter to $5.13B.

Based on Artal Group's 13F filing for Q1 2016, filed 12 May 2016.